SCHEMBL30516377

SCHEMBL30516377

CC(C)(C)OC(=O)N1CCN(c2cccc(NCc3cccc(Cl)c3)c2N)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HTT P42858 1/20 0.46
KCNQ2 O43526 2/20 0.45
TP53 P04637 1/20 0.44
MET P08581 1/20 0.44
ADORA2A P29274 1/20 0.44
MAPK8 P45983 1/20 0.44
MAPK1 P28482 1/20 0.43
STS P08842 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
PBRM1 Q86U86 1/20 0.42
CCNT1 O60563 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21301932 1.00 ACHE (0.47) ACHESMN1; SMN2NPSR1HTTKCNQ2
SCHEMBL30516367 0.93 SMN1; SMN2 (0.46) ACHESMN1; SMN2NPSR1HTTMET
SCHEMBL21301974 0.93 SMN1; SMN2 (0.46) ACHESMN1; SMN2NPSR1HTTMET
SCHEMBL21301986 0.90 MAPK8 (0.47) ACHESMN1; SMN2NPSR1HTTKCNQ2
SCHEMBL30516368 0.90 MAPK8 (0.47) ACHESMN1; SMN2NPSR1HTTKCNQ2
SCHEMBL3853111 0.89 ACHE (0.58) ACHESMN1; SMN2NPSR1HTTMET
SCHEMBL31066764 0.89 ACHE (0.58) ACHESMN1; SMN2NPSR1HTTMET
SCHEMBL21301987 0.89 P2RX7 (0.46) ACHESMN1; SMN2NPSR1HTTTP53
SCHEMBL30516387 0.89 P2RX7 (0.46) ACHESMN1; SMN2NPSR1HTTTP53
SCHEMBL4616010 0.89 ACHE (0.46) ACHESMN1; SMN2NPSR1HTTKCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2025-06-03 US disclosed
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed Pharma S.A (PL) 2024-08-29 US disclosed
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C ACHE 287/4885SMN1; SMN2 3365/4885NPSR1 26/4885
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C ACHE 324/4885SMN1; SMN2 3307/4885NPSR1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.